Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors

Conclusion High (8.2%) CAT incidence during ICI administration suggested that ICI is not associated with a lower blood clot risk than other anticancer agents investigated in previous studies. For patients with VTE, ATE, or heart disease history, it is crucial to consider the possibility of CAT even with antiplatelet therapy.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research